ClinicalTrials.gg
CompletedNCT05515601Updated Jul 5, 2024Results posted

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector compared to mirikizumab (reference) solution given via autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.

Screening is required within 35 days prior to enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Have a ( BMI) within the range of 18.0 to 34.0 kg/m2, inclusive.
  • are males or non-pregnant women of (WOCBP) or women not of childbearing potential (WNOCBP).

Exclusion criteria

Exclusion Criteria:

  • Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy
  • Have an abnormal blood pressure, pulse rate, or temperature as determined by the investigator
  • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing
  • Are lactating or pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Mirikizumab (Reference)

    200 milligram (mg) of mirikizumab as reference formulation \[100 mg/milliliter (mL)\], 2 × 1-mL autoinjector administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.

    Drug: Mirikizumab

  • Experimental
    Mirikizumab (Test)

    200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL autoinjector administered as a SC injection into the arm/thigh/abdomen on day 1.

    Drug: Mirikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

    PK: Cmax of mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab

    PK: AUC\[0-∞\] of Mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab

    PK: AUC\[0-tlast\] of Mirikizumab was evaluated.

    Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose

07

Results

Posted Jul 5, 2024

Participant flow

Participant flow — Overall Study
Milestone200 Milligram (mg) Mirikizumab (Reference): Abdomen200 mg Mirikizumab (Reference): Arm200 mg Mirikizumab (Reference): Thigh200 mg Mirikizumab (Test): Abdomen200 mg Mirikizumab (Test): Arm200 mg Mirikizumab (Test): Thigh
Started636967666665
Received at least 1 dose of study drug636967666665
Completed626665656464
Not completed132121
Withdrew: Withdrawal by subject132111
Withdrew: Lost to follow-up000010

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab

PK: Cmax of mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
micrograms per milliliter (μg/mL)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab13.0 ± 4212.9 ± 40
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 0.986 · 90% CI 0.929 to 1.05
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab

PK: AUC\[0-∞\] of Mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab
microgram*day per milliliter (μg*day/mL)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Mirikizumab229 ± 43232 ± 42
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 1.01 · 90% CI 0.948 to 1.08
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab

PK: AUC\[0-tlast\] of Mirikizumab was evaluated.

Time frame:
Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
Reported as:
Geometric mean · μg*day/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab
μg*day/mL200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Mirikizumab225 ± 42231 ± 41
Statistical analysis
  • 200 mg Mirikizumab (Reference) vs 200 mg Mirikizumab (Test) · Ratio of geometric least squares mean: 1.02 · 90% CI 0.960 to 1.09

Adverse events

Collected over Baseline Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Mirikizumab (Reference): Abdomen0/63 (0%)0/63 (0%)11/63 (17.5%)
200 mg Mirikizumab (Reference): Arm0/69 (0%)0/69 (0%)12/69 (17.4%)
200 mg Mirikizumab (Reference): Thigh0/67 (0%)0/67 (0%)13/67 (19.4%)
200 mg Mirikizumab (Test): Abdomen0/66 (0%)0/66 (0%)7/66 (10.6%)
200 mg Mirikizumab (Test): Arm0/66 (0%)0/66 (0%)11/66 (16.7%)
200 mg Mirikizumab (Test): Thigh0/65 (0%)0/65 (0%)12/65 (18.5%)
Most frequent other events
Most frequent other events
Event200 mg Mirikizumab (Reference): Abdomen200 mg Mirikizumab (Reference): Arm200 mg Mirikizumab (Reference): Thigh200 mg Mirikizumab (Test): Abdomen200 mg Mirikizumab (Test): Arm200 mg Mirikizumab (Test): Thigh
Injection site reactionGeneral disorders10/6310/6912/674/666/669/65
HeadacheNervous system disorders2/634/692/673/667/663/65

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
Mean40.7 ± 13.041.1 ± 12.240.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
Female98104202
Male10193194
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
Hispanic or Latino363369
Not Hispanic or Latino163164327
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
American Indian or Alaska Native000
Asian11617
Native Hawaiian or Other Pacific Islander000
Black or African American293059
White150152302
More than one race9918
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)200 mg Mirikizumab (Reference)200 mg Mirikizumab (Test)Total
United States199197396
08

Study locations

6 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • Axis
    Dilworth, Minnesota 56529, United States
  • QPS
    Springfield, Missouri 65802, United States
  • Labcorp Clinical Research LP
    Dallas, Texas 75247, United States
  • LabCorp CRU, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2023, 5 months.

Results were first posted in Jul 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 25, 2022
StartActual
Aug 31, 2022
Primary completionActual
Feb 20, 2023
CompletionActual
Feb 20, 2023
Results first posted
Jul 5, 2024
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05515601
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Aug 31, 2022
Primary completion
Feb 20, 2023
Completion
Feb 20, 2023
Results posted
Jul 5, 2024
Last update
Jul 5, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion